Recent News

• 05.14.2025 - ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2025
• 05.12.2025 - ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2025
• 04.08.2025 - ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 of 2025
• 04.07.2025 - ImmuCell Hires Chief Financial Officer
• 04.02.2025 - ImmuCell Announces Initiation of Investigational Product Use of Re-Tain®
• 02.25.2025 - ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2024
• 02.20.2025 - ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2024

Recent Filings

• 05.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.14.2025 - 8-K Current report
• 05.14.2025 - EX-99.1 EX-99.1
• 04.24.2025 - DEF 14A Other definitive proxy statements
• 04.23.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.08.2025 - 8-K Current report
• 04.08.2025 - EX-99.1 EX-99.1
• 04.07.2025 - 3 Initial statement of beneficial ownership of securities
• 04.07.2025 - 8-K Current report
• 04.07.2025 - EX-99.1 EX-99.1